Viltepso viltolarsen fda approval date?

When did the FDA approve Viltepso?
Viltepso (viltolarsen) received FDA approval on 13 August 2024 under accelerated‑approval status for patients with Duchenne muscular dystrophy carrying a specific deletion in exon 51 of the DMD gene. [1]

What does Viltepso treat?
It is the first antisense oligonucleotide therapy that restores the reading frame of dystrophin in exon 51‑deletion patients, potentially slowing muscle loss.

Why is this approval significant?
Viltepso expands the growing portfolio of exon‑skipping drugs for Duchenne muscular dystrophy, offering a new treatment option for a subgroup that previously had few choices.

Who makes Viltepso?
The drug is developed and marketed by Roche Genomics (a Roche company).

What does the accelerated‑approval pathway mean?
Approval is based on a surrogate endpoint—dystrophin production—rather than full clinical benefit data, with post‑market studies required to confirm effectiveness.

How can patients access Viltepso?
Patients must have a confirmed exon 51‑deletion diagnosis and a physician’s prescription. Roche offers a patient‑assistance program to help with costs and insurance navigation.

Is Viltepso covered by insurance?
Most major insurers list it under specialty drug coverage, but prior authorization and coverage verification are typically required.

What are the next steps for Roche after approval?
Roche plans to submit the post‑approval study data that will determine whether the accelerated approval can be converted to full approval and will monitor safety signals as the drug enters the market.

Sources
[1] https://www.drugpatentwatch.com.